Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma-Reference-Cited by-同舟云学术

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

Published:2021-11-02 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Leupin Nicolas¹,Zinzani Pier Luigi²³^ORCID,Morschhauser Franck⁴,Dalle Stéphane⁵,Maerevoet Marie⁶,Michot Jean‐Marie⁷^ORCID,Ribrag Vincent⁷,Offner Fritz⁸,Beylot‐Barry Marie⁹,Moins‐Teisserenc Hélène¹⁰^ORCID,Zwaenepoel Karen¹¹,Winne Koen¹¹,Battistella Maxime¹⁰,Hultberg Anna¹,Gandini Domenica¹,Moshir Mahan¹,Jacobs Julie¹^ORCID,Delahaye Tim¹,Khan Aitzaz¹,Zabrocki Piotr¹,Silence Karen¹,Rompaey Luc¹,Borg Christophe¹²,Motta Giovanna¹³,Melle Federica¹³,Calleri Angelica¹³,Pauwels Patrick¹¹,Haard Hans¹,Pileri Stefano¹³,Bagot Martine¹⁴

Affiliation:

1. Argenx Zwijnaarde Belgium

2. IRCCS Azienda Ospedaliero–Universitaria di Bologna Bologna Italy

3. Istituto di Ematologia “Seràgnoli,” Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università degli Studi Bologna Italy

4. Groupe de Recherche sur les Formes Injectables et les Technologies Associées Université de Lille, CHU Lille, EA 7365 Lille France

5. Department of Dermatology Centre Hospitalier Lyon Sud Pierre Bénite France

6. Service Hématologie Institut Jules Bordet Brussels Belgium

7. Gustave Roussy Villejuif France

8. University Hospital Gent Gent Belgium

9. Inserm U1053, Department of Dermatology Centre Hospitalier Bordeaux France

10. Hôpital Saint Louis, Université de Paris, INSERM U1160 Paris France

11. Department of Pathology University Hospital Antwerp Edegem Belgium